Technology | Vascular Closure Devices | November 05, 2018

Cordis Launches Mynx Control Vascular Closure Device

November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S. launch of Mynx Control Vascular Closure Device (VCD). It integrates active extravascular sealing and bioresorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5-7 French femoral arterial access sites. Vascular closure devices reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional procedures.

The Mynx Control VCD features a deployment system that is designed for predictable deployment and ease of use. It will be available in 5 French as well as 6/7 French sizes. Highlights of this new system include:

  • Sheath catch that is compatible with the procedural sheath;

  • Tension indicator that provides visual confirmation of device position for proper sealant deployment; and

  • Ergonomic handle with a 2-button deployment design to simplify procedural steps. 

Leveraging the MynxGrip VCD technology, which has been used in over 2 million interventional cases worldwide, the Mynx Control VCD utilizes a dual-mode active sealing mechanism. This allows the sealant to interlock with the contours of the arterial wall, expanding to fill the tissue tract and create a matrix structure for clot formation. With all closure components resorbing within 30 days, nothing is left behind. The Mynx VCD technology has shown it can to reduce surgical complications, expedite recovery, shorten hospital stays and increase patient comfort.[1-5]

For more information: cardinalhealth.com

 

References:

 

1. Pruski MJ Jr, Blachut AM, Konkolewska M, et al. MynxGrip for closure of antegrade puncture after peripheral interventions with same-day discharge. Vasc Endovasc Surg. 2017 Feb;51(2):67-71.

2. Baker NC, Escarcega RO, Lipinski MJ, et al. Active versus passive anchoring vascular closure devices following percutaneous coronary intervention: a safety and efficacy comparative analysis. J Interv Cardiol. 2016 Feb; 29(1): 108-112.

3. Hutchings D, Hayat A, Karunakaran A, Malik N. Success, safety, and efficacy of the Mynx femoral closure device in a real-world cohort: single-center experience. J Invasive Cardiol. 2016 Mar;28(3): 104-108.

4. Noor S, Meyers S, Curl R. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. Vasc Endovascular Surg. 2010 Jul;44(5):345-349.

5. Fargen KM, Hoh BL, Mocco J. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device. J NeuroInterv Surg. 2011 Sep; 3(3): 219-223.

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...